Lv2
190 积分 2024-06-25 加入
ACNP 60th Annual Meeting: Poster Abstracts P276 – P550
25天前
已完结
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions—Part 2
1个月前
已关闭
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions—Part 1
1个月前
已关闭
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
1个月前
已关闭
Development and preclinical evaluation of NYM074 as a novel Theranostic ligand targeting carbonic anhydrase IX in renal cell carcinoma
1个月前
已完结
Toxicity and dosimetry of177Lu-DOTA-Y3-octreotate in a rat model
1个月前
已完结
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
2个月前
已关闭
Evaluation of the safety, biodistribution, dosimetry of [18F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial
2个月前
已完结
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
2个月前
已完结
Phase 1 Dose-Escalation Study of [ 225 Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
2个月前
已关闭
皖公网安备34019202002308
